"DNA Mismatch Repair" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A DNA repair pathway involved in correction of errors introduced during DNA replication when an incorrect base, which cannot form hydrogen bonds with the corresponding base in the parent strand, is incorporated into the daughter strand. Excinucleases recognize the BASE PAIR MISMATCH and cause a segment of polynucleotide chain to be excised from the daughter strand, thereby removing the mismatched base. (from Oxford Dictionary of Biochemistry and Molecular Biology, 2001)
| Descriptor ID |
D053843
|
| MeSH Number(s) |
G02.111.222.220 G05.219.220
|
| Concept/Terms |
DNA Mismatch Repair- DNA Mismatch Repair
- Mismatch Repair, DNA
- Repair, DNA Mismatch
- Mismatch Repair
- Repair, Mismatch
|
Below are MeSH descriptors whose meaning is more general than "DNA Mismatch Repair".
Below are MeSH descriptors whose meaning is more specific than "DNA Mismatch Repair".
This graph shows the total number of publications written about "DNA Mismatch Repair" by people in this website by year, and whether "DNA Mismatch Repair" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 3 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 2 | 3 |
| 2022 | 2 | 2 | 4 |
| 2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Mismatch Repair" by people in Profiles.
-
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D. Clin Cancer Res. 2025 Feb 17; 31(4):667-677.
-
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer. 2025 Jan 04; 13(1).
-
Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry. Cancer Genet. 2025 Jan; 290-291:44-50.
-
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025 Mar; 36(3):277-284.
-
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precis Oncol. 2024 Nov; 8:e2400419.
-
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. J Clin Oncol. 2025 Jan 20; 43(3):251-259.
-
Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. Eur J Cancer. 2024 Nov; 212:114336.
-
Clinical Updates and Surveillance Recommendations for DNA Replication Repair Deficiency Syndromes in Children and Young Adults. Clin Cancer Res. 2024 Aug 15; 30(16):3378-3387.
-
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma. Oncoimmunology. 2024; 13(1):2384667.
-
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Immunother Cancer. 2024 May 31; 12(5).